Oxidative Stress and Dopaminergic Metabolism : A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net.
Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta. ROS produced during the metabolism of dopamine is immediately neutralized by the endogenous antioxidant defense system (EADS) under physiological conditions. Aging decreases the vigilance of EADS and makes the dopaminergic neurons more vulnerable to oxidative stress. As a result, ROS left over by EADS oxidize the dopamine-derived catechols and produces a number of reactive dopamine quinones, which are precursors to endogenous neurotoxins. In addition, ROS causes lipid peroxidation, uncoupling of the electron transport chain, and DNA damage, which lead to mitochondrial dysfunction, lysosomal dysfunction, and synaptic dysfunction. The mutations in genes such as DNAJC6, SYNJ1, SH3GL2, LRRK2, PRKN, and VPS35 caused by ROS have been associated with synaptic dysfunction and the pathogenesis of Parkinson’s disease (PD). The available drugs that are used against PD can only delay the progression of the disease, but they produce various side effects. Through their antioxidant activity, flavonoids can substantiate the EADS of dopaminergic neurons and disrupt the vicious cycle incepted by oxidative stress. In this review, we show how the oxidative metabolism of dopamine generates ROS and dopamine-quinones, which then exert unrestrained OS, causing mutations in several genes involved in the proper functioning of mitochondrion, synapse, and lysosome. Besides, we also present some examples of approved drugs used for the treatment of PD, therapies in the clinical trial phase, and an update on the flavonoids that have been tested to boost the EADS of dopaminergic neurons.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - (2023) vom: 09. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rasool, Aamir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidants |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1871527322666230609141519 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358048958 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358048958 | ||
| 003 | DE-627 | ||
| 005 | 20231226073919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527322666230609141519 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358048958 | ||
| 035 | |a (NLM)37303175 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rasool, Aamir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxidative Stress and Dopaminergic Metabolism |b A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net | ||
| 520 | |a Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta. ROS produced during the metabolism of dopamine is immediately neutralized by the endogenous antioxidant defense system (EADS) under physiological conditions. Aging decreases the vigilance of EADS and makes the dopaminergic neurons more vulnerable to oxidative stress. As a result, ROS left over by EADS oxidize the dopamine-derived catechols and produces a number of reactive dopamine quinones, which are precursors to endogenous neurotoxins. In addition, ROS causes lipid peroxidation, uncoupling of the electron transport chain, and DNA damage, which lead to mitochondrial dysfunction, lysosomal dysfunction, and synaptic dysfunction. The mutations in genes such as DNAJC6, SYNJ1, SH3GL2, LRRK2, PRKN, and VPS35 caused by ROS have been associated with synaptic dysfunction and the pathogenesis of Parkinson’s disease (PD). The available drugs that are used against PD can only delay the progression of the disease, but they produce various side effects. Through their antioxidant activity, flavonoids can substantiate the EADS of dopaminergic neurons and disrupt the vicious cycle incepted by oxidative stress. In this review, we show how the oxidative metabolism of dopamine generates ROS and dopamine-quinones, which then exert unrestrained OS, causing mutations in several genes involved in the proper functioning of mitochondrion, synapse, and lysosome. Besides, we also present some examples of approved drugs used for the treatment of PD, therapies in the clinical trial phase, and an update on the flavonoids that have been tested to boost the EADS of dopaminergic neurons | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a ROS | |
| 650 | 4 | |a antioxidants | |
| 650 | 4 | |a dopaminergic neuron | |
| 650 | 4 | |a flavonoids. | |
| 650 | 4 | |a oxidative stress | |
| 700 | 1 | |a Manzoor, Robina |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah, Kaleem |e verfasserin |4 aut | |
| 700 | 1 | |a Afzal, Ramsha |e verfasserin |4 aut | |
| 700 | 1 | |a Ul-Haq, Asad |e verfasserin |4 aut | |
| 700 | 1 | |a Imran, Hadia |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleem, Imdad |e verfasserin |4 aut | |
| 700 | 1 | |a Akhtar, Tanveer |e verfasserin |4 aut | |
| 700 | 1 | |a Farrukh, Anum |e verfasserin |4 aut | |
| 700 | 1 | |a Hameed, Sahir |e verfasserin |4 aut | |
| 700 | 1 | |a Bashir, Shahid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g (2023) vom: 09. Juni |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:09 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527322666230609141519 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 09 |c 06 | ||